Association Between Kidney Function and Outcomes Following Immune Checkpoint Inhibitor-Based Combination Therapy in Patients with Advanced Renal Cell Carcinoma

•The aim of this study is to clarify whether clinical outcomes following immune checkpoint inhibitor-based combination therapy differ according to the baseline kidney function of patients with advanced renal cell carcinoma.•The efficacy of IO-IO and IO-TKI treatments in terms of survival and tumor response rate was not affected by kidney function.•The rates of severe AEs, treatment interruption, and corticosteroid administration were not different based on the CKD grade in the IO-IO group.•In the IO-TKI group, the incidence of severe AEs and rate of immune checkpoint inhibitor interruption increased according to the CKD grade, while the corticosteroid administration rate was also likely to be higher in patients with CKD.